Company Overview
About Vial
Vial is a clinical research organization (CRO) founded in 2020 by Simon Burns and Jason Wang and headquartered in San Francisco, California. The company has built a technology-enabled model for running clinical trials that differs from traditional CROs by directly partnering with clinical practices — particularly in dermatology and ophthalmology — and converting them into research sites. Vial handles the full operational burden: regulatory and IRB submissions, site staff training, clinical equipment provisioning, electronic data capture (EDC) setup, and patient recruitment and scheduling. This allows clinics with no prior research experience to participate in trials, dramatically expanding the pool of available sites and accelerating patient enrollment timelines.
Business Model & Competitive Advantage
Vial raised a $77M Series B in 2022 led by Meritech Capital with participation from GV (Google Ventures), Andreessen Horowitz (a16z), and others, bringing total funding to approximately $100M. The company serves biotech and pharmaceutical sponsors that are running Phase 1 through Phase 3 trials, offering a full-service CRO model with proprietary technology infrastructure for trial management, data collection, and site coordination. By owning the site relationship and technology stack end-to-end, Vial can offer faster site activation timelines and more predictable enrollment than traditional CROs that rely on a broker-like model across pre-existing independent sites.
Competitive Landscape 2025–2026
The tech-enabled CRO space is evolving rapidly, with Vial competing against legacy players like ICON, Parexel, and Covance, as well as newer entrants including Lindus Health and Headlands Research. Vial's initial focus on dermatology has expanded into other therapeutic areas, and its model of direct clinic ownership (or tight operational partnership) positions it as part of a broader movement to decentralize and accelerate clinical research through technology.
Key Differentiators
Strong Challenger
Vial is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare Vial with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Vial? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Vial Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Vial vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →